Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial
2004 ◽
Vol 22
(14_suppl)
◽
pp. 513-513
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 513-513
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 1018-1018
2005 ◽
Vol 23
(16_suppl)
◽
pp. 613-613
◽
2014 ◽
Vol 106
(5)
◽
2007 ◽
Vol 13
(10)
◽
pp. 2977-2985
◽
Keyword(s):
2002 ◽
Vol 11
(2)
◽
pp. 415-421
◽
Keyword(s):